A turning point for our Big Pharma

There is an attempt to quickly set up a national vaccine production project. In the shortage of government indications, following the previous hangover, there is a lot of talk about it and tending to take it very seriously. But neither the aims nor the tools of the plan are clear and shareable. Italy is a net exporter of pharmaceuticals, but it is not the country that holds the richest part of the production chain, namely that of research and development. To understand, Italian companies, or rather, based in Italy, are specialized in the production and packaging phase of the drug. This is the situation and perhaps it is not the preferable one, but to change the balance, a strong investment in risk capital would be needed and a very solid connection between private research centers, public universities and hospitals, in order to launch the first phase of the supply chain in Italy.

Subscribe to continue reading

Are you already a subscriber? Log in Stay informed wherever you are thanks to our digital offer

The inquiries, the editorials, the newsletters. The major current events on the devices you prefer, daily insights from Italy and the world

The web sheet at € 8.00 for one month Discover all the solutions


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick